The trajectory of Viagra, formerly marketed by copyright, presents a fascinating case study for investors considering the pharmaceutical arena . While its groundbreaking success and generation of billions in revenue , the intellectual property end has opened the door for competing medications, significantly reducing earnings opportunities. This tra